Shanghai Nianxing Industrial Co., Ltd
China
Product Name: CFI-400437
Price: Check
Purity: 98.0%
Stocking Period: 10 Day
Contact: Yang
Email: sales@echemcloud.com

1169211-37-3

1169211-37-3 structure

1169211-37-3 structure

Name: CFI-400437
Chemical Name: CFI-400437
CAS Number: 1169211-37-3
Molecular Formula: C₂₉H₂₈N₆O₂
Molecular Weight: 492.57
Catalog: Signaling Pathways Cell Cycle/DNA Damage Polo-like Kinase (PLK)
Create Date: 2021-12-19 20:31:36
Modify Date: 2025-08-26 18:43:02
CFI-400437 is an indolinone-derived, ATP-competitive kinase inhibitor with high selectivity for PLK4 (IC50 of 0.6 nM)[1].

Name	CFI-400437

Description	CFI-400437 is an indolinone-derived, ATP-competitive kinase inhibitor with high selectivity for PLK4 (IC50 of 0.6 nM)[1].
Related Catalog	Research Areas >> Cancer Signaling Pathways >> Cell Cycle/DNA Damage >> Polo-like Kinase (PLK)
In Vitro	CFI-400437 is a potent inhibitor of MCF-7, MDA-MB-468 and MDA-MB231 cell growth[1]. CFI-400437 inhibits Aurora A, Aurora B, KDR and FLT-3 with IC50s of 0.37, 0.21, 0.48, and 0.18 µM, respectively, i.e. two orders of magnitude higher than its IC50 of 0.6 nM against PLK4[1]. CFI-400437 inhibits both AURKB and AURKC at concentrations <15 nM[2].
In Vivo	CFI-400437 (25 mg/kg, ip, once daily for 21 d) exhibits antitumor activity against MDA-MB-468 breast cancer mouse xenograft model[1].
References	[1]. Radoslaw Laufer, et al. The discovery of PLK4 inhibitors: (E)-3-((1H-Indazol-6-yl)methylene)indolin-2-ones as novel antiproliferative agents. J Med Chem. 2013 Aug 8;56(15):6069-87. [2]. Amreena Suri, et al. Evaluation of Protein Kinase Inhibitors with PLK4 Cross-Over Potential in a Pre-Clinical Model of Cancer. Int J Mol Sci. 2019 Apr 29;20(9):2112.

Molecular Formula	C₂₉H₂₈N₆O₂
Molecular Weight	492.57

The content on this webpage is sourced from various professional data sources. If you have any questions or concerns regarding the content, please feel free to contact service1@chemsrc.com.